AVEO Pharmaceuticals (AVEO) Downgraded by BidaskClub
BidaskClub cut shares of AVEO Pharmaceuticals (NASDAQ:AVEO) from a sell rating to a strong sell rating in a research report sent to investors on Tuesday.
A number of other research firms also recently weighed in on AVEO. B. Riley restated a buy rating and set a $5.00 target price on shares of AVEO Pharmaceuticals in a research report on Tuesday, January 16th. assumed coverage on AVEO Pharmaceuticals in a research report on Wednesday, November 15th. They set a buy rating and a $5.00 target price for the company. Finally, Zacks Investment Research upgraded AVEO Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, January 9th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $4.05.
Shares of AVEO Pharmaceuticals (NASDAQ AVEO) opened at $2.87 on Tuesday. The firm has a market capitalization of $339.54, a price-to-earnings ratio of -4.04 and a beta of 1.38. AVEO Pharmaceuticals has a 52-week low of $0.50 and a 52-week high of $4.24. The company has a debt-to-equity ratio of -0.32, a quick ratio of 2.33 and a current ratio of 2.33.
TRADEMARK VIOLATION WARNING: “AVEO Pharmaceuticals (AVEO) Downgraded by BidaskClub” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/aveo-pharmaceuticals-aveo-downgraded-by-bidaskclub/1903237.html.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.